Daya S
McMaster University, Department of Obstetrics & Gynecology, Clinical Epidemiology & Biostatistics, HSC-3N52, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5.
Cochrane Database Syst Rev. 2007 Jul 18(1):CD001299. doi: 10.1002/14651858.CD001299.
Gonadotropin releasing hormone agonists (GnRHa) are used in assisted reproduction cycles to reversibly block pituitary function and prevent a luteinizing hormone surge. In the short and ultrashort protocols of GnRHa administration, injection of gonadotropins is commenced a few days after the start of GnRHa. In the long protocols (with GnRHa started either in the midluteal phase or in the early follicular phase) gonadotropin administration is delayed until pituitary desensitization has been achieved, usually 2-3 weeks.
To conduct a systematic overview of available data comparing short or ultrashort and long GnRHa protocols for pituitary desensitization in in vitro fertilization (IVF) and gamete intra-fallopian transfer (GIFT) treatment cycles.
Search strategies included on-line searching of the MEDLINE and EMBASE data bases and the Cochrane Menstrual Disorders and Subfertility Group's Specialised Register from 1982 to 1998, and hand searching of bibliographies of relevant publications and reviews, and abstracts of scientific meetings.
Randomized trials of short or ultrashort versus long (follicular or luteal phase start) GnRHa protocols in IVF or GIFT treatment cycles.
Data were extracted into 2 x 2 tables. For the primary outcome, clinical pregnancy per cycle started, the overall common odds ratio (OR) and the risk difference with 95% confidence interval (CI) were calculated after verifying the presence of homogeneity of treatment effect across all trials. The following subgroup comparisons were performed: ultrashort versus long protocols, short versus long protocols and, within each of these comparisons, subgroups of studies which used the long protocol with follicular phase start or the long protocol with luteal phase start. Secondary outcomes considered were clinical pregnancy per oocyte retrieval and per embryo transfer, spontaneous abortion, ongoing/delivered pregnancy per cycle started, number of ampoules of gonadotropin used, number of oocytes retrieved, and fertilization rate.
Twenty-six trials met the inclusion criteria. The common OR for clinical pregnancy per cycle started was 1.32 (95% CI , 1.10 - 1.57) in favour of the long GnRHa protocol. The studies were subgrouped, depending on whether, in the long protocol, the GnRHa was commenced in the follicular phase (8 trials) or luteal phase (16 trials). The respective ORs were 1.54 (95% CI, 1.11 - 2.13) and 1.21 (95% CI, 0.98 - 1.51). After excluding the four trials using the ultrashort protocol, the OR for long versus short protocols (22 trials) was 1.27 (95% CI, 1.04 - 1.56). A comparison of long versus ultrashort protocols (4 trials) produced an OR of 1.47 (95% CI, 1.02 - 2.12).
AUTHORS' CONCLUSIONS: On the basis of clinical pregnancy rate per cycle started, this meta-analysis demonstrates the superiority of the long protocol over the short and ultrashort protocols for GnRHa use in IVF and GIFT cycles.
促性腺激素释放激素激动剂(GnRHa)用于辅助生殖周期,以可逆性阻断垂体功能并防止促黄体生成素峰。在GnRHa给药的短方案和超短方案中,在GnRHa开始使用几天后开始注射促性腺激素。在长方案中(GnRHa在黄体中期或卵泡早期开始使用),促性腺激素给药延迟至实现垂体脱敏,通常为2 - 3周。
对现有数据进行系统综述,比较在体外受精(IVF)和配子输卵管内移植(GIFT)治疗周期中用于垂体脱敏的GnRHa短方案或超短方案与长方案。
检索策略包括1982年至1998年在线检索MEDLINE和EMBASE数据库以及Cochrane月经紊乱和生育力低下小组的专业注册库,并手工检索相关出版物和综述的参考文献以及科学会议的摘要。
IVF或GIFT治疗周期中GnRHa短方案或超短方案与长方案(卵泡期或黄体期开始)的随机试验。
数据提取到2×2表格中。对于主要结局,即每个开始周期的临床妊娠,在验证所有试验中治疗效果的同质性后,计算总体共同优势比(OR)和95%置信区间(CI)的风险差。进行了以下亚组比较:超短方案与长方案、短方案与长方案,并且在这些比较中的每一个中,将使用卵泡期开始的长方案或黄体期开始的长方案进行研究亚组划分。考虑的次要结局包括每次取卵和每次胚胎移植后的临床妊娠、自然流产、每个开始周期的持续/分娩妊娠、使用的促性腺激素安瓿数量、取卵数量以及受精率。
26项试验符合纳入标准。每个开始周期临床妊娠的共同OR为1.32(95%CI,1.10 - 1.57),支持GnRHa长方案。根据长方案中GnRHa是在卵泡期(8项试验)还是黄体期(16项试验)开始,对研究进行亚组划分。各自的OR分别为1.54(95%CI,1.11 - 2.13)和1.21(95%CI,0.98 - 1.51)。在排除使用超短方案的4项试验后,长方案与短方案(22项试验)的OR为1.27(95%CI,1.04 - 1.56)。长方案与超短方案(4项试验)的比较产生的OR为1.47(95%CI,1.02 - 2.12)。
基于每个开始周期的临床妊娠率,该荟萃分析表明在IVF和GIFT周期中使用GnRHa时,长方案优于短方案和超短方案。